Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 200,000 shares at $36.62 ($7.3M) on 2026-09-30, disclosed to the SEC on 2026-10-02.
Scheduled sale ($7.3M) by President & Immunovant CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |
| ROIV | SELL | 2026-06-26 | $6.6M | — | Filing → |